Molecular Markers of Hemostatic Activation: Applications in the Diagnosis of Thrombosis and Vascular and Thrombotic Disorders

Clinical and Applied Thrombosis/Hemostasis

Volumn 1, Issue 2, 1995, Pages 87-102

  Fareed, Jawed ^a   Bick, Rodger L ^b   Hoppensteadt, Debra A ^a   Bermes, Edward W ^a  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS AT DALLAS   (United States)

Author keywords

Enzyme linked immunosorbent assay; Hypercoagulable state; Molecular markers; Tissue factor; Tissue factor pathway inhibitor

Indexed keywords

EID: 84965431152     PISSN: 10760296     EISSN: 19382723     Source Type: Journal    
DOI: 10.1177/107602969500100201     Document Type: Article

References (27)

1. Fareed J., Messmore HL, Bermes EW New perspectives in coagulation testing. Clin Chem 1980; 26: 1380-91.
2. Harker LA, Ross R. Pathogenesis of arterial vascular disease. Semin Thromb Hemost 1979; 5: 274-92.
3. Hirsh J. Blood tests for the diagnosis of venous and arterial thrombosis. Blood 1981; 57: 1-8.
4. Kitchens CS Concept of hypercoagulability: a review of its development, clinical application, and recent progress. Semin Thromb Hemost 1985;11: 293-315.
5. Reddy VB, Kowal-Vern A., Hoppensteadt D., et al. Global and molecular hemostatic markers in acute myeloid leukemia. Am J Clin Pathol 1990; 94(4):397-403.
6. Brandtzaeg P., Sandset PM, Joe GB, et al. The quantitative association of plasma endotoxin, antithrombin, protein C, extrinsic pathway inhibitor and fibrinopeptide A in systemic meningococcal disease. Thromb Res 1989; 55: 459-70.
7. Fareed J., Bick RL, Squillaci G., et al. Molecular markers of hemostatic disorders: implications in the diagnosis and therapeutic management of thrombotic and bleeding disorders. Clin Chem 1983; 29(9):1641-58.
8. Fareed J., Walenga JM, Bick RL, et al. Low molecular weight markers of hemostatic defects: impact of automation on the quantitation of hemostatic disorders. Semin Thromb Hemost 1983; 9(4):354-78.
9. Messmore HL, Walenga JM, Fareed J. Molecular markers of platelet activation. Semin Thromb Hemost 1984; 10(4): 264-9.
10. Bauer KA, Rosenberg RD The pathophysiology of the pro-thrombotic state in humans: insights gained from studies using markers of hemostatic system activation. Blood 1987; 70: 343-50.
11. Bach R., Gentry R., Nemersoa Y. Factor VII binding to tissue factor in reconstituted phospholipid vesicles: induction of cooperativity by phosphatidylserine. Biochemistry 1986; 25: 4007.
12. Broze G., Miletich JP Characterization of the inhibition of tissue factor in serum. Blood 1987; 69: 150-5.
13. Broze G., Warren J., Novotny LA, et al. The lipoprotein associated coagulation inhibitor that inhibits the factor VIIa-tissue factor complex also inhibits factors Xa: insight into its possible mechanism of action. Blood 1988;71: 335-43.
14. Hoppensteadt D., Fareed J., Walenga JM, et al. Measurement of functional and immunologic levels of tissue factor pathway inhibitor: some methodologic considerations. Blood 1993; 82(10):2458.
15. Aurousseau MH, Amiral J., Boffa MC Level of plasma thrombomodulin in neonates and children. Thromb Haemost 1991;65(6): 1232 (Abstr 1937).
16. Stephens CJM. The antiphospholipid syndrome: clinical correlations, cutaneous features, mechanism of thrombosis and treatment of patients with the lupus anticoagulant and anticardiolipin antibodies. Br J Dermatol 1991; 125: 199-210.
17. Walenga JM, Hoppensteadt D. Automation in hemostasis. In: Schoeff LE, Williams RH, eds. Principles of laboratory instruments. St. Louis: Mosby Year Book, Inc., 1993: 379-95.
18. Fareed J., Walenga JM, Baker WH, et al. Molecular markers of hemostatic activation in atherosclerosis: a new concept in diagnostic profiling of endogenous pathophysiologic transition. Semin Thromb Hemost 1986; 12: 102-9.
19. Fareed J., Walenga JM Changing trends in hemostatic testing. In: Okuda K, ed. Automation and new technology in the clinical laboratory. Oxford: Blackwell Scientific, 1990: 203-10.
20. Fareed J., Baker WH, Walenga JM, et al. Molecular markers of hemostatic activation: future perspectives. Semin Thromb Hemost 1984; 10(4):329-32.
21. Amiral J., Adalbert B., Adam M. Application of enzyme immunoassays to coagulation testing. Clin Chem 1984; 30: 1512-6.
22. Pareed J., Moncada R., Messmore HL, et al. Molecular markers of contrast media-induced adverse reactions. Semin Thromb Hemost 1984; 10(4):306-28.
23. Fareed J., Walenga JM, Saravia G., et al. Thrombogenic potential of nonionic contrast media? Radiology 1990; 174: 321-5.
24. Lewy RI, Weiner L., Smith JB, et al. Detection of plasma concentrations of thromboxane B2 in Prinzmetat's variant angina and clinical angina pectoris. Clin Cardiol 1979; 2: 404-7.
25. Sidoli A., Galliani S., Baralle FE DNA based diagnostic tests: recombinant DNA and cardiovascular disease risk factors. Br Med Bull 1990; 46(4):941-59.
26. Walenga JM, Pifarre R. Hemostatic alterations in myocardial infarction and use of newer laboratory methods in diagnosis and prognosis. In: Pifarre R, ed. Cardiac surgery: state of the art reviews. Philadelphia, PA: Hanely and Belfus, Inc., 1992: 1-16.
27. Bajaj MS, Rana SW, Wysomerski RB, et al. Inhibitor of the factor VIIa-tissue factor complex is reduced in patients with disseminated intravascular coagulation but not in patients with severe hepatocellular disease. J Clin Invest 1987; 79: 1874-8.